Your browser doesn't support javascript.
loading
Clinical relevance of 18F-FDG-negative osteoblastic metastatic bone lesions noted on PET/CT in breast cancer patients.
Al-Muqbel, Kusai M; Yaghan, Rami J; Al-Omari, Ma'moon H; Rousan, Liqa A; Dagher, Nawaf M; Al Bashir, Samir.
Afiliación
  • Al-Muqbel KM; Departments of aRadiology and Nuclear Medicine bSurgery cPathology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Nucl Med Commun ; 37(6): 593-601, 2016 Jun.
Article en En | MEDLINE | ID: mdl-26813990
ABSTRACT

PURPOSE:

Our study aims to assess the clinical relevance of fluorine-18 fluorodeoxyglucose (F-FDG) negative osteoblastic metastatic bone lesions noted on PET/computed tomography (CT) in breast cancer patients. PATIENTS AND

METHODS:

The medical records of breast cancer patients were reviewed retrospectively from January 2012 until April 2015. We included the patients who had metastatic bone disease evaluated by F-FDG-PET/CT. Group 1 included patients with newly diagnosed metastatic bone disease at the time of imaging and group 2 included patients with a history of treated metastatic bone disease at the time of imaging. Functional and structural bone abnormality was monitored on F-FDG-PET/CT scans.

RESULTS:

Fifty-three patients, median age 47.1 years (range 27-80 years), were included. Group 1 included 35 patients. Of those, 88% had predominantly F-FDG-avid osteolytic and mixed lesions (destructive pattern). Complete response was noted in 65% of the patients after treatment, evidenced by disappearance of bony focal activity with partial or total ossification of most osteolytic lesions converting into mixed and 'secondary' osteoblastic lesions. In addition, more ossified lesions were noted in some patients whose lesions were left untreated for long time (aged lesions). The remaining 12% of group 1 patients had pure 'primary' osteoblastic lesions (nondestructive pattern), which started small and expanded with time and tend to be F-FDG-negative. Group 2 included 18 patients who had predominantly mixed and 'secondary' osteoblastic lesions.

CONCLUSION:

We described two types of osteoblastic metastatic bone lesions in breast cancer patients 'primary' and 'secondary'. 'Secondary' lesions (88%) are totally ossified (healed) osteolytic lesions and are almost always F-FDG-negative on PET/CT. These lesions are of no clinical importance. Healing is potentially seen after treatment or if the lesions are left untreated for a long time (aged lesions). 'Primary' lesions (12%) are seen without previous bone destruction and tend to be F-FDG-negative, although they contain tumor cells. Hence, sequential CT is more helpful than sequential FDG-PET in following 'primary' lesions.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Osteólisis / Neoplasias Óseas / Neoplasias de la Mama / Fluorodesoxiglucosa F18 / Tomografía Computarizada por Tomografía de Emisión de Positrones Tipo de estudio: Diagnostic_studies / Etiology_studies Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Nucl Med Commun Año: 2016 Tipo del documento: Article País de afiliación: Jordania

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Osteólisis / Neoplasias Óseas / Neoplasias de la Mama / Fluorodesoxiglucosa F18 / Tomografía Computarizada por Tomografía de Emisión de Positrones Tipo de estudio: Diagnostic_studies / Etiology_studies Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Nucl Med Commun Año: 2016 Tipo del documento: Article País de afiliación: Jordania